Trials / Completed
CompletedNCT03779815
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography
A Pilot Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]Florbetaben Positron Emission Tomography for Detecting Amyloidosis in Multiple Myeloma Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Ulsan University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
\[18F\]Florbetaben PET/CT imaging will noninvasively assess amyloid deposition in systemic amyloidosis.
Detailed description
Diagnostic validity of \[18F\]Florbetaben PET for detecting amyloidosis will be assessed in subjects with multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]Florbetaben | * Drug: \[18F\]Florbetaben * \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma * Other name: Neuraceq * Amount: 300 MBq ± 20% bolus, 10mL intravenously |
Timeline
- Start date
- 2018-08-20
- Primary completion
- 2019-02-28
- Completion
- 2019-02-28
- First posted
- 2018-12-19
- Last updated
- 2019-04-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03779815. Inclusion in this directory is not an endorsement.